Minnan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minnan Yang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Biao Kan
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
1 shared publication - Changgui Li
National Institutes for Food and Drug Control, Beijing, China
1 shared publication - Cheng-Feng Qin
State Key Laboratory of Pathogen and Biosecurity Academy of Military Medical Sciences Beijing China
1 shared publication - Chuan Qin
Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Deyu Jiang
Sinovac Biotech Ltd., Beijing, China
1 shared publication - Dongdong Wu
Sinovac Biotech Ltd., Beijing, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6499) , 77-81
Development of an inactivated vaccine candidate for SARS-CoV-2
Vaccine candidate tested in monkeys: Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al. report preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies. The researchers obtained multiple SARS-CoV-2 strains from 11 hospitalized patients across the world and then chemically inactivated the harmful properties of the virus. Animals were immunized with one of two vaccine doses and then inoculated with SARS-CoV-2. Those that received the lowest dose showed signs of controlling the infection, and those receiving the highest dose appeared more protected and did not have detectable viral loads in the pharynx or lungs at 7 days after infection. The next steps will be testing for safety and efficacy in humans. Science , this issue p. 77
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6499) , 77-81
Top Cited PapersOpen AccessDevelopment of an inactivated vaccine candidate for SARS-CoV-2
Vaccine candidate tested in monkeys: Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al. report preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies. The researchers obtained multiple SARS-CoV-2 strains from 11 hospitalized patients across the world and then chemically inactivated the harmful properties of the virus. Animals were immunized with one of two vaccine doses and then inoculated with SARS-CoV-2. Those that received the lowest dose showed signs of controlling the infection, and those receiving the highest dose appeared more protected and did not have detectable viral loads in the pharynx or lungs at 7 days after infection. The next steps will be testing for safety and efficacy in humans. Science , this issue p. 77